Knocking on TGF-β's Gate: Why Integrin Inhibitors Are Back in the Spotlight
Exploring the latest developments in anti-fibrotic strategies targeting tissue-specific TGF-β activation via αvβ6/αvβ1 integrins.
Introduction
TGF-β (Transforming Growth Factor-β) is one of the most important cytokines promoting fibrosis. However, since TGF-β is also essential for immune regulation and wound healing, direct inhibition can cause severe side effects.
An approach to solve this problem focuses on inhibiting tissue-specific TGF-β activation via integrins. Integrins function as "gatekeepers" for TGF-β, converting latent TGF-β to its active form.
Mechanism: Integrins and TGF-β Activation
Structure of Latent TGF-β
TGF-β is secreted as a latent complex bound to LAP (Latency-Associated Peptide). This complex is stored by binding to LTBP (Latent TGF-β Binding Protein) in the extracellular matrix (ECM).
Integrin-Mediated Activation
Specific integrins bind to the RGD sequence within LAP and apply mechanical force to release and activate TGF-β.
Key Integrin Isoforms
| Integrin | Primary Expression | TGF-β Activation | Disease Relevance |
|---|---|---|---|
| αvβ6 | Epithelial cells (lung, liver, kidney) | High | IPF, MASH |
| αvβ1 | Fibroblasts | High | Pan-fibrosis |
| αvβ8 | Immune cells, neurons | Moderate | Autoimmune, neurological |
| αvβ3 | Vascular endothelium, osteoclasts | Low | Angiogenesis, bone remodeling |
Integrin Inhibitors in Development
Key Pipeline
| Compound | Target | Developer | Stage | Indication | Status |
|---|---|---|---|---|---|
| Bexotegrast (PLN-74809) | αvβ6/αvβ1 | Pliant Therapeutics | Phase 2b/3 | IPF | Discontinued (2025) |
| IDL-2965 | αvβ1/αvβ3/αvβ6 | Indalo Therapeutics | Phase 1/2 | IPF, MASH | Ongoing |
| GSK3008348 | αvβ6 | GSK | Phase 1 | IPF | Completed (safety only) |
| BG00011 (STX-100) | αvβ6 antibody | Biogen | Phase 2 | IPF | Completed |
Lessons from Bexotegrast
Pliant Therapeutics' Bexotegrast was the most advanced integrin inhibitor, but the Phase 2b/3 BEACON-IPF trial was discontinued in 2025.
Reasons for Discontinuation:
- Independent data safety monitoring board noted imbalance in IPF-related adverse events compared to placebo
- Specific adverse event details not publicly disclosed
Possible Challenges:
- Selectivity issues: Simultaneous inhibition of αvβ6 and αvβ1 may have caused unexpected effects
- Dose optimization: Balance between degree of inhibition and safety
- Patient selection: Lack of proper stratification using appropriate biomarkers
Future of Integrin Targeting Strategies
Next-Generation Approaches
- Single isoform-selective inhibition: Selectively inhibit only αvβ6 or only αvβ1
- Inhaled formulations: Reduce systemic exposure through local pulmonary delivery (for IPF)
- PROTACs: Induced degradation of integrin proteins
Importance of Biomarkers
Appropriate patient selection is essential for success of integrin inhibition therapy:
- αvβ6 expression levels: Evaluation in BAL fluid or biopsy specimens
- Imaging biomarkers: Visualization using integrin-targeted PET tracers
- Blood biomarkers: Active TGF-β levels, ECM metabolites
Evaluation in Preclinical Models
Recommended Models
| Model | Advantage | Evaluation Endpoints |
|---|---|---|
| Bleomycin lung fibrosis | Confirmed αvβ6 upregulation | Lung function, collagen, αvβ6 IHC |
| CDAA MASH | αvβ1 expression in hepatic stellate cells | Liver fibrosis score, Sirius Red |
| UUO renal fibrosis | Rapid fibrosis induction | Integrin expression, α-SMA |
Key Evaluation Points
- Target occupancy: Confirm degree of integrin inhibition after dosing
- Active TGF-β measurement: Tissue and blood levels
- Downstream signaling: Western blot or IHC for pSmad2/3
Summary
Integrin inhibition is a promising approach to "smart" TGF-β suppression, but as the discontinuation of Bexotegrast demonstrates, balancing isoform selectivity and safety is critical. Next-generation integrin inhibitors, when more selective and administered to appropriate patients, have the potential to become breakthroughs in fibrosis treatment.
Accurately evaluating integrin expression at the preclinical stage and confirming target engagement is key to clinical success.
References
- Henderson NC, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19(12):1617-1624.
- Munger JS, et al. The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96(3):319-328.
- Pliant Therapeutics Press Release (2025): BEACON-IPF Trial Discontinuation.
- Reed NI, et al. The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Sci Transl Med. 2015;7(288):288ra79.